Bristol-Myers upgraded at Leerink
Leerink Partners, the health-care advisory firm, has continued a recent recruitment drive with hires from boutiques ...
Leerink downgraded 908 Devices (MASS) to Market Perform from Outperform with a price target of $4, down from $12. Though the firm still sees ...
Fintel on MSN17h
Leerink Partners Downgrades 908 Devices (MASS)Fintel reports that on November 13, 2024, Leerink Partners downgraded their outlook for 908 Devices (NasdaqGM:MASS) from ...
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Leerink Partners analyst Mani Foroohar maintained a Hold rating on CureVac (CVAC – Research Report) on November 12. The company’s ...
Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) – Leerink Partnrs cut their FY2024 EPS estimates for Celldex ...
Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...
Shares of Hims & Hers Health slumped 15% on Thursday after Amazon.com launched a rival service that offers upfront pricing ...
Investment analysts at Leerink Partnrs lifted their FY2024 earnings per share (EPS) estimates for shares of Xencor in a ...
Zai Lab intends to use the net proceeds from this offering for general corporate purposes. Goldman Sachs (Asia) L.L.C., ...
Leerink notes that Syndax (SNDX) has disclosed topline pivotal data for menin-MLL inhibitor revumenib in NPM1m acute leukemia, which the firm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback